Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Tegoprubart · AT-1501

Monoclonal antibody · Antagonist of CD40 ligand (CD40LG) · developed by Eledon Pharmaceuticals

Phase 3 Most advanced trial

ELDN Developer

3 Registered trials

What is Tegoprubart?

Tegoprubart (AT-1501) is an investigational agent given by intravenous infusion.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: AT-1501
Drug type: Monoclonal antibody
Targets: CD40 ligand (CD40LG)
Mechanism: Antagonist of CD40 ligand (CD40LG)
Therapy area: Endocrine, Immunology
Developer: Eledon Pharmaceuticals (ELDN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: EK87C62XNH

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07835581	Phase 3	Kidney Transplant Rejection	Not yet recruiting	ELDN
NCT05480657	Phase 1/2	Brittle Type 1 Diabetes Mellitus	Withdrawn	ELDN
NCT05027906	Phase 1/2	Prevention of Rejection in Kidney Transplant	Recruiting	ELDN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Kidney Transplant RejectionPrevention of Rejection in Kidney TransplantBrittle Type 1 Diabetes Mellitus

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the ELDN page.

Follow ELDN, the company behind Tegoprubart

See ELDN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ELDN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z